Menu Close
Donata Medaglini

Donata Medaglini is Professor of Microbiology, Head of the Laboratory of Microbial Immunity in the Department of Medical Biotechnology and Vice-Rector for Life Sciences at the University of Siena. She is the Vice-President of the Sclavo Vaccines Association. She is the Italian Representative in the H2020 Programme Committee on “Nanotechnologies, Advanced materials, Biotechnology and Advanced Manufacturing and Processing”. She has more than 25 years of research activity in the field of microbiology, mucosal immunology and vaccines. She holds a PhD in Microbiology from the University of Genova. From 1992-1994 she was Research Associate in the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University (New York). From 1996 till 2001 she was non-tenured Professor of Microbiology at the University of Siena. From 2001-2003 she was National Expert at the European Commission, DG Research, Poverty-related Diseases Unit. Since 2003 is Professor of Microbiology at the University of Siena. She is author/co-author of several publications in international peer-reviewed journals. She has extensive experience in the scientific coordination of large collaborative projects (MUVAPRED, 2003-2009). She is the Project Coordinator of the IMI2 JU VSV-EBOPLUS project on “Systems analysis of adult and pediatric responses to the VSV-ZEBOV Ebola vaccine” and IMI2 JU VSV-EBOVAC project (http://www.vsv-ebovac.eu) on “Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV”, and the Managing Entity Coordinator of IMI FLUCOP project (http://www.flucop.eu) on “Standardization and Development of Assays for Assessment of Influenza Vaccine Correlates of Protection” involving 22 partners. She was also the Scientific Coordinator of the FP7 High Impact Project on Advanced Immunization Technologies “ADITEC” (www.aditecproject.eu) involving 42 partners from 12 EU countries and USA and is responsible for the dissemination activities of the IMI BIOVACSAFE project on “Biomarkers of Immune Vaccine Safety”.